The drug BMF-219 works by increasing, preserving and reactivating patients’ own healthy insulin-producing cells. Read more at ...

In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

As the rate of myopia in children grows, research is keeping a finger pointed at the fact much of our lives is spent indoors.

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...

Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share.

Babies conceived through assisted reproductive technology are more likely to be born with a major heart defect, new research ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...

The many health benefits of essential oils range from reducing stress to fighting infectious diseases. Find out if using them ...

The U.S. Food and Drug Administration (FDA) passed a critical mandate regarding dense breast tissue. Here's what it means for ...

FDA alerts in gastroenterology over the summer included an approval for a biosimilar for IBD & new indications for nonerosive ...